The Myeloma Community Just Proposed the Definition of a Cure. Here’s What You Need to Know.

Last week, the International Myeloma Society (IMS) convened a historic meeting to answer a question our community has asked for decades: What does “cure” mean in multiple myeloma?

Over a day and a half, MMRF representatives and nearly 100 clinicians, researchers, industry partners, patient advocates, and patients came together in person, with more than 1,000 participating virtually. Together, we reviewed data spanning more than 30 years—the advent of Total Therapy pioneered at the University of Arkansas in the 1990s through today’s most advanced immunotherapies—to understand what depth and duration of response may truly predict long-term remission and cure.

Based on this meeting, the new proposed definition of a cure for multiple myeloma is:

Patients who are MRD-negative (meaning there are no myeloma cells detected among 1,000,000 plasma cells) and have been off all anti-myeloma therapy for five years may be considered cured.

This marks a profound shift for myeloma research and care.

Cure—Without Compromise

To create a proposed definition, attendees discussed three essential criteria for a cure:

1. Effective therapy of finite duration
2. No evidence of disease
3. No relapse after stopping therapy

For years, continuous therapy has been the standard paradigm, with many patients on treatment indefinitely. But a cure means something fundamentally different and more patient-centered: no detectable disease and no need for ongoing treatment.

Importantly, this proposed definition applies to all patients: newly diagnosed or heavily pretreated, standard-risk or high-risk. Cure, we all agreed, should mean the same thing for every myeloma patient.

One critical caveat: Attendees agreed that cure cannot come at the expense of irreversible side effects or second cancers. Patients should expect not only freedom from myeloma, but to have a normal life expectancy and quality of life.

Defining cure is a watershed moment. Yet today, very few patients meet this five-year, treatment-free benchmark. That reality underscores how much work remains.

Powerful Patient Stories

The most inspiring moments at the meeting came from two extraordinary patients.

One underwent an allogeneic transplant more than 30 years ago and remains disease-free today. The other participated in the CARTITUDE-1 trial of the CAR T-cell therapy Carvykti® and has been off treatment for over seven years with no evidence of disease.

Their experiences and those of other long-term survivors remind us that cure is no longer theoretical—it is possible.

Meeting attendees also heard from leaders in lymphoma, testicular cancer, and lung cancer, where “cure” is already part of the standard vocabulary. Their frameworks helped inform the discussion of what this means for myeloma patients and for the design of clinical trials aiming to test cures.

The Roadmap to Cure

The MMRF is committed to leading the next chapter of this work. Our Foundation’s key priorities include:

• Identifying which current and emerging therapies have curative potential
• Understanding which patients are most likely to be cured with specific treatments
• Matching the right patient to the right potentially curative therapy
• Developing new options for patients who are unlikely to be cured with today’s treatments
• Ensuring curative strategies do not create unacceptable long-term risks
• Studying patients who live treatment-free with low-level disease (such as those reverting to an MGUS-like state)
• Advancing blood-based MRD testing to reduce reliance on bone marrow biopsies

Earlier this year, the MMRF launched the first study in our Translational Research Umbrella (TRU) program, enrolling 150 patients receiving BCMA-targeted CAR T-cell or bispecific antibody therapies as part of standard care. By deeply analyzing tumor biology, immune response, and the microbiome, we aim to understand who benefits most—including who may be cured—and why.

Importantly, gleaning insights into why some people can be considered cured will inform faster, better-designed clinical trials of potential curative treatments. Through our Horizon Clinical Trials Program, we will soon launch additional studies specifically designed with curative intent, building on insights from TRU.

A Historic Moment

For more than 25 years, the MMRF’s mission has been to accelerate a cure for every patient. For much of that time, “cure” felt aspirational. Our focus was ensuring patients lived longer, with new therapies always on the horizon, while we worked to better understand the biology of the disease.

Today, we stand at a turning point. Cure is no longer just a hope. It is an achievable goal.

But achieving it for every patient will require urgency, collaboration, and relentless focus. The MMRF will continue to lead and partner across the community until cure is not the exception, but the expectation—and until we can close our doors because our work is done.